Literature DB >> 28316331

Targeted therapies: Ibrutinib: new option for relapsed MZL.

Lisa Hutchinson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28316331     DOI: 10.1038/nrclinonc.2017.26

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

Authors:  Ariela Noy; Sven de Vos; Catherine Thieblemont; Peter Martin; Christopher R Flowers; Franck Morschhauser; Graham P Collins; Shuo Ma; Morton Coleman; Shachar Peles; Stephen Smith; Jacqueline C Barrientos; Alina Smith; Brian Munneke; Isaiah Dimery; Darrin M Beaupre; Robert Chen
Journal:  Blood       Date:  2017-02-06       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.